These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 27896490)

  • 1. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.
    Abdo WF; Bloem BR; Van Geel WJ; Esselink RA; Verbeek MM
    Neurobiol Aging; 2007 May; 28(5):742-7. PubMed ID: 16678934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
    Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; Vogt IR; Brandt M; Hansen N; Glanz W; Brockmann K; Spottke A; Hoffmann DC; Peters O; Priller J; Wiltfang J; Düzel E; Schneider A; Falkenburger B; Klockgether T; Gasser T; Nuscher B; Haass C; Höglinger G; Levin J
    J Neurol; 2024 Oct; 271(10):6991-6999. PubMed ID: 39254698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study.
    Singer W; Schmeichel AM; Sletten DM; Gehrking TL; Gehrking JA; Trejo-Lopez J; Suarez MD; Anderson JK; Bass PH; Lesnick TG; Low PA
    Clin Auton Res; 2023 Dec; 33(6):635-645. PubMed ID: 37603107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
    Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Suarez MD; Misra PP; Soto C; Low PA
    Ann Neurol; 2021 Jun; 89(6):1212-1220. PubMed ID: 33881777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.
    Tokutake T; Kasuga K; Tsukie T; Ishiguro T; Shimohata T; Onodera O; Ikeuchi T
    Parkinsonism Relat Disord; 2022 Sep; 102():30-35. PubMed ID: 35933820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.
    Herbert MK; Aerts MB; Beenes M; Norgren N; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Front Neurol; 2015; 6():91. PubMed ID: 25999911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis.
    Cong S; Xiang C; Wang H; Cong S
    J Neurol; 2021 Aug; 268(8):2703-2712. PubMed ID: 32162061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease: A protocol for systematic review and meta-analysis.
    Wang H; Wang W; Shi H; Han L; Pan P
    Medicine (Baltimore); 2020 Jul; 99(31):e21458. PubMed ID: 32756166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
    Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia.
    Abdo WF; van de Warrenburg BP; Munneke M; van Geel WJ; Bloem BR; Kremer HP; Verbeek MM
    Neurology; 2006 Aug; 67(3):474-9. PubMed ID: 16894110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.